One Wealth Capital Management LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

One Wealth Capital Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,606 shares of the medical research company’s stock, valued at approximately $835,000.

Several other large investors also recently made changes to their positions in TMO. Diversified Trust Co lifted its holdings in shares of Thermo Fisher Scientific by 25.5% in the fourth quarter. Diversified Trust Co now owns 12,784 shares of the medical research company’s stock valued at $6,651,000 after purchasing an additional 2,594 shares in the last quarter. Bangor Savings Bank raised its stake in shares of Thermo Fisher Scientific by 6.0% during the 4th quarter. Bangor Savings Bank now owns 334 shares of the medical research company’s stock worth $174,000 after purchasing an additional 19 shares in the last quarter. Oliver Luxxe Assets LLC grew its stake in shares of Thermo Fisher Scientific by 6.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 9,461 shares of the medical research company’s stock valued at $4,922,000 after buying an additional 555 shares in the last quarter. Doliver Advisors LP raised its position in Thermo Fisher Scientific by 1.6% during the fourth quarter. Doliver Advisors LP now owns 2,803 shares of the medical research company’s stock worth $1,458,000 after acquiring an additional 44 shares in the last quarter. Finally, Kings Path Partners LLC increased its stake in shares of Thermo Fisher Scientific by 13.1% during the 4th quarter. Kings Path Partners LLC now owns 2,637 shares of the medical research company’s stock worth $1,372,000 after purchasing an additional 306 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TMO shares. Scotiabank assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price objective for the company. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Bernstein Bank boosted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. TD Cowen lifted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Finally, Evercore ISI decreased their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $650.05.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock valued at $25,954,465 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 1.5 %

NYSE:TMO traded up $8.17 on Tuesday, hitting $545.36. The stock had a trading volume of 1,370,654 shares, compared to its average volume of 1,612,948. The company has a market cap of $208.60 billion, a PE ratio of 34.19, a P/E/G ratio of 3.54 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The business’s fifty day moving average is $530.39 and its 200 day moving average is $568.53. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business’s revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.69 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific declared that its board has approved a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.